Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 360

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

Julien, Sylvia, Merino-Trigo, Ana, Lacroix, Ludovic, Pocard, Marc, Goéré, Diane, Mariani, Pascale, Landron, Sophie, Bigot, Ludovic, Nemati, Fariba, Dartigues, Peggy, Weiswald, Louis-Bastien, Lantuas, Denis, Morgand, Loïc, Pham, Emmanuel, Gonin, Patrick, Dangles-Marie, Virginie, Job, Bastien, Dessen, Philippe, Bruno, Alain, Pierré, Alain, De Thé, Hugues, Soliman, Hany, Nunes, Manoel, Lardier, Guillaume, Calvet, Loreley, Demers, Brigitte, Prévost, Grégoire, Vrignaud, Patricia, Roman-Roman, Sergio, Duchamp, Olivier, Berthet, Cyril·2012·Clinical Cancer Research

Abstract

Purpose: Patient-derived xenograft models are considered to represent the heterogeneity of human cancers and advanced preclinical models. Our consortium joins efforts to extensively develop and characterize a new collection of patient-derived colorectal cancer (CRC) models. Experimental Design: From the 85 unsupervised surgical colorectal samples collection, 54 tumors were successfully xenografted in immunodeficient mice and rats, representing 35 primary tumors, 5 peritoneal carcinoses and 14 metastases. Histologic and molecular characterization of patient tumors, first and late passages on mice includes the sequence of key genes involved in CRC (i.e., APC, KRAS, TP53), aCGH, and transcriptomic analysis. Results: This comprehensive characterization shows that our collection recapitulates the clinical situation about the histopathology and molecular diversity of CRC. Moreover, patient tumors and corresponding models are clustering together allowing comparison studies between clinical and preclinical data. Hence, we conducted pharmacologic monotherapy studies with standard of care for CRC (5-fluorouracil, oxaliplatin, irinotecan, and cetuximab). Through this extensive in vivo analysis, we have shown the loss of human stroma cells after engraftment, observed a metastatic phenotype in some models, and finally compared the molecular profile with the drug sensitivity of each tumor model. Through an experimental cetuximab phase II trial, we confirmed the key role of KRAS mutation in cetuximab resistance. Conclusions: This new collection could bring benefit to evaluate novel targeted therapeutic strategies and to better understand the basis for sensitivity or resistance of tumors from individual patients. Clin Cancer Res; 18(19); 5314–28. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-0372

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 360

Metadata

Authors
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., Weiswald, L.-B., Lantuas, D., Morgand, L., Pham, E., Gonin, P., Dangles-Marie, V., Job, B., Dessen, P., Bruno, A., Pierré, A., De Thé, H., Soliman, H., Nunes, M., Lardier, G., Calvet, L., Demers, B., Prévost, G., Vrignaud, P., Roman-Roman, S., Duchamp, O., & Berthet, C.
Venue
Clinical Cancer Research
Published
2012-09-30
Volume
18
Issue
19
Pages
5314-5328
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2083802683
Cited by
360
References
29
FWCI
11.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0372
The paper
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., Weiswald, L.-B., Lantuas, D., Morgand, L., Pham, E., Gonin, P., Dangles-Marie, V., Job, B., Dessen, P., Bruno, A., . . . Berthet, C. (2012). Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0372

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.